BR112016029041A8 - uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico - Google Patents

uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico

Info

Publication number
BR112016029041A8
BR112016029041A8 BR112016029041A BR112016029041A BR112016029041A8 BR 112016029041 A8 BR112016029041 A8 BR 112016029041A8 BR 112016029041 A BR112016029041 A BR 112016029041A BR 112016029041 A BR112016029041 A BR 112016029041A BR 112016029041 A8 BR112016029041 A8 BR 112016029041A8
Authority
BR
Brazil
Prior art keywords
inhibitor
pharmaceutical
glutaminase inhibitor
glutaminase
pharmaceutical composition
Prior art date
Application number
BR112016029041A
Other languages
English (en)
Other versions
BR112016029041A2 (pt
Inventor
L Mackinnon Andrew
Zhang Dong
Parlati Francesco
L Rodriguez Mirna
M Steggerda Susanne
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of BR112016029041A2 publication Critical patent/BR112016029041A2/pt
Publication of BR112016029041A8 publication Critical patent/BR112016029041A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

terapia de combinação com inibidores de glutaminase. a invenção refere-se a métodos de tratar câncer, doenças mieloproliferativas, ou doenças imunológicas ou neurológicas com uma combinação de um inibidor de glutaminase e um agente anticâncer tal como um inibidor de enzima (tal como um inibidor de cinase), um inibidor mitótico, um agente de modificação de dna ou um análogo de citidina. a invenção também se refere a métodos de tratar câncer, doenças mieloproliferativas, ou doenças imunológicas ou neurológicas que são resistentes a um ou mais agentes anticâncer.
BR112016029041A 2014-06-13 2015-06-12 uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico BR112016029041A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462012061P 2014-06-13 2014-06-13
US201562149487P 2015-04-17 2015-04-17
PCT/US2015/035577 WO2015192014A1 (en) 2014-06-13 2015-06-12 Combination therapy with glutaminase inhibitors

Publications (2)

Publication Number Publication Date
BR112016029041A2 BR112016029041A2 (pt) 2017-08-22
BR112016029041A8 true BR112016029041A8 (pt) 2021-07-20

Family

ID=54834405

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029041A BR112016029041A8 (pt) 2014-06-13 2015-06-12 uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico

Country Status (13)

Country Link
US (2) US9687485B2 (pt)
EP (1) EP3154590B1 (pt)
JP (1) JP6798890B2 (pt)
KR (1) KR20170012562A (pt)
CN (1) CN107027291B (pt)
AU (1) AU2015274361B2 (pt)
BR (1) BR112016029041A8 (pt)
CA (1) CA2952213A1 (pt)
EA (1) EA036001B1 (pt)
IL (1) IL249476A0 (pt)
MX (1) MX2016016364A (pt)
SG (1) SG11201610333VA (pt)
WO (1) WO2015192014A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
LT2920168T (lt) 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterociklinis gliutaminazės inhibitorius
MA39926B1 (fr) 2014-04-30 2019-12-31 Pfizer Dérivés de dihétérocycle liés à cycloalkyle
MX2016016364A (es) 2014-06-13 2017-04-06 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
SG11201700816YA (en) 2014-08-07 2017-02-27 Calithera Biosciences Inc Crystal forms of glutaminase inhibitors
BR112017020780A2 (pt) * 2015-03-30 2018-06-26 Calithera Biosciences Inc métodos de administração de inibidores de glutaminase
KR20170132333A (ko) * 2015-04-06 2017-12-01 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제에 의한 폐암의 치료
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
CA2994256A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
ES2957583T3 (es) 2015-07-31 2024-01-22 Univ Johns Hopkins Profármacos de análogos de la glutamina
AU2016335991A1 (en) 2015-10-05 2018-05-10 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
CN109503570B (zh) * 2015-12-18 2020-08-25 诺言医药科技(上海)有限公司 一种含有索拉非尼的药物组合物及其应用
US9757859B1 (en) 2016-01-21 2017-09-12 X Development Llc Tooltip stabilization
US9744665B1 (en) 2016-01-27 2017-08-29 X Development Llc Optimization of observer robot locations
US10059003B1 (en) 2016-01-28 2018-08-28 X Development Llc Multi-resolution localization system
SG11201901389XA (en) 2016-08-25 2019-03-28 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
CN109982703A (zh) * 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
US10980835B2 (en) * 2016-12-02 2021-04-20 Beth Israel Deaconess Medical Center, Inc. Arsenic trioxide for treatment of PIN1-associated disorders
CN108210461A (zh) * 2016-12-16 2018-06-29 中国科学院上海药物研究所 一种Talazoparib药物组合物及其应用
WO2018165516A1 (en) * 2017-03-10 2018-09-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN108721304B (zh) * 2017-04-17 2020-10-16 北京大学 用于***的药物组合物及其用途
CU20190105A7 (es) * 2017-06-22 2020-10-20 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico y composiciones farmacéuticas de esta
US20190269705A1 (en) * 2017-11-27 2019-09-05 Regents Of The University Of Minnesota Methods and materials for treating graft versus host disease
WO2019200216A1 (en) * 2018-04-12 2019-10-17 The Methodist Hospital System Modulation of irf-4 and uses thereof
CN108715882A (zh) * 2018-05-31 2018-10-30 中国人民解放军军事科学院军事医学研究院 通过有丝***阻滞诱导的细胞叠套结构模型及其制备方法
CN110732025A (zh) * 2018-07-19 2020-01-31 中国人民解放军军事科学院军事医学研究院 一种cell-in-cell结构的动物模型及其制备方法
IT201800009974A1 (it) * 2018-10-31 2020-05-01 Universita' Degli Studi Di Milano - Bicocca Trattamento combinato farmacologico per cancro
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
WO2020246737A1 (ko) * 2019-06-04 2020-12-10 사회복지법인 삼성생명공익재단 콰시노이드를 포함하는 거세 저항성 전립선암 치료용 조성물
CN111643669A (zh) * 2020-06-30 2020-09-11 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 谷氨酰胺酶抑制剂在制备治疗银屑病的药物中的应用
CN114699398A (zh) * 2022-04-26 2022-07-05 中国人民解放军陆军特色医学中心 一种用于治疗肾透明细胞癌的抑制剂
WO2023209625A1 (en) * 2022-04-28 2023-11-02 Scirosbio (Fzc) Compositions and methods for treatment of cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
JP3979783B2 (ja) 1997-07-29 2007-09-19 アルコン ラボラトリーズ インコーポレイテッド ガラクトマンナンポリマー及びホウ酸塩を含む眼科組成物
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2578680C (en) 2004-04-15 2011-06-14 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
CN101951930A (zh) 2008-02-19 2011-01-19 阿奈斯特药品株式会社 对身体功能的恢复有用的口服或经肠组合物
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) * 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
MX2013005434A (es) 2010-11-18 2013-09-26 Deuteria Pharmaceuticals Inc 3´ - deutero - polidomida.
CA2742342A1 (en) * 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
DE112012002938A5 (de) 2011-07-13 2014-04-24 Dr. Hielscher Gmbh Verfahren und Einrichtung zur Eigenschaftsänderung wenigstens eines flüssigen Mediums
FI20115876A0 (fi) * 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
CN103030597B (zh) * 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
EA201692166A1 (ru) 2011-11-21 2017-07-31 Калитера Байосайенсиз Инк. Гетероциклические ингибиторы глютаминазы
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
BR112015005243A2 (pt) 2012-09-10 2017-07-04 Celgene Corp métodos para o tratamento de câncer de mama localmente avançado
ES2690829T3 (es) * 2012-09-17 2018-11-22 Agios Pharmaceuticals, Inc. Uso de e-cadherina y vimentina para la selección de pacientes que responden al tratamiento
LT2920168T (lt) 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterociklinis gliutaminazės inhibitorius
KR20150085078A (ko) 2012-11-21 2015-07-22 아지오스 파마슈티컬스 아이엔씨. 글루타마제 억제제 및 사용 방법
US9029531B2 (en) * 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
AU2013356241A1 (en) * 2012-12-03 2015-07-09 Calithera Biosciences, Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
WO2015138902A1 (en) 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
MX2016016364A (es) 2014-06-13 2017-04-06 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
SG11201700816YA (en) 2014-08-07 2017-02-27 Calithera Biosciences Inc Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
US10517844B2 (en) 2014-11-13 2019-12-31 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Also Published As

Publication number Publication date
US9687485B2 (en) 2017-06-27
CN107027291B (zh) 2020-10-30
EP3154590A4 (en) 2018-01-24
MX2016016364A (es) 2017-04-06
SG11201610333VA (en) 2017-01-27
JP6798890B2 (ja) 2020-12-09
JP2017517548A (ja) 2017-06-29
WO2015192014A1 (en) 2015-12-17
EA201692511A1 (ru) 2017-06-30
KR20170012562A (ko) 2017-02-02
CA2952213A1 (en) 2015-12-17
EP3154590B1 (en) 2021-04-14
US20160022674A1 (en) 2016-01-28
CN107027291A (zh) 2017-08-08
AU2015274361B2 (en) 2020-11-05
AU2015274361A1 (en) 2017-01-12
US20170333430A1 (en) 2017-11-23
EA036001B1 (ru) 2020-09-11
EP3154590A1 (en) 2017-04-19
BR112016029041A2 (pt) 2017-08-22
IL249476A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
AU2024202345A1 (en) Nucleic acid carriers and therapeutic methods of use
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018014154A (es) Polinucleotidos moduladores.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EP4219713A3 (en) Products and compositions
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
ECSP14013148A (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
WO2016130581A3 (en) Combination cancer therapy
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements